AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.46) by 76.09 percent. This is a 91.79 percent increase over losses of $(1.34) per share from the same period last year. The company reported quarterly sales of $27.488 million which beat the analyst consensus estimate of $21.675 million by 26.82 percent. This is a 23.47 percent increase over sales of $22.263 million the same period last year.